2021 CAEP Acute Atrial Fibrillation/Flutter Best Practices Checklist

TY - JOUR

T1 - 2021 CAEP Acute Atrial Fibrillation/Flutter Best Practices Checklist

N1 - Funding Information: The 2018 Checklist project was funded by a research grant from the Cardiac Arrhythmia Network and the resultant guidelines were formally endorsed by the Canadian Association of Emergency Physicians (CAEP). We chose to adapt, for use by emergency physicians, existing high-quality clinical practice guidelines (CPG) previously developed by the Canadian Cardiovascular Society (CCS) [-]. These CPGs were developed and revised using a rigorous process that is based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system of evaluation []. With the assistance of our PhD methodologist (IG), we used the recently developed Canadian CAN-IMPLEMENT© process adapted from the ADAPTE Collaboration [, ]. We created an Advisory Committee consisting of ten academic emergency physicians (one also expert in thrombosis medicine), four community emergency physicians, three cardiologists, one PhD methodologist, and two patients. Our focus was four key elements of ED care: assessment and risk stratification, rhythm and rate control, short-term and long-term stroke prevention, and disposition and follow-up. The advisory committee communicated by face-to-face meetings, teleconferences, and email. The checklist was prepared and revised through a process of feedback and discussion on all issues by all panel members. These revisions went through ten iterations until consensus was achieved. We then circulated the draft checklist for comment to approximately 300 emergency medicine and cardiology colleagues. Finally, the CAEP Standards Committee posted the Checklist online for all CAEP members to provide feedback (Fig. ). Funding Information: Funding for this guideline was supported by the Cardiac Arrhythmia Network of Canada (CANet) as part of the Networks of Centres of Excellence (NCE). Dr. Stiell has received unrestricted research support from InCarda Therapeutics and Cipher Pharmaceuticals. Dr. Angaran has received research funding and/or honoraria from BMS-Pfizer Alliance and Servier, Dr. DeWit has received research funding from Bayer. Dr. Deyell has received honoraria and research funding from Biosense Webster, Bayer, Bristol-Myers-Squibb, Abbott, and Servier. Dr. Skanes has received honoraria from Boehringer Ingelheim, Bayer, Pfizer, and Servier. Dr. Tebbenham has received honoraria from Cardiome Pharma Corp. We thank the hundreds of Canadian emergency physicians and cardiologists who reviewed the draft guidelines and who provided very helpful feedback.

PY - 2021/9

Y1 - 2021/9

UR - http://www.scopus.com/inward/record.url?scp=85112373426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85112373426&partnerID=8YFLogxK

U2 - 10.1007/s43678-021-00167-y

DO - 10.1007/s43678-021-00167-y

M3 - Review article

C2 - 34383280

AN - SCOPUS:85112373426

SN - 1481-8035

VL - 23

SP - 604

EP - 610

JO - Canadian Journal of Emergency Medicine

JF - Canadian Journal of Emergency Medicine

IS - 5

ER -